Background Recent progesterone trials call for an update of previous syntheses of interventions to prevent preterm birth.
Introduction
Globally, about 15 million pregnancies each year end in preterm birth, 1 i.e. before the 37th week of gestation, which is a major cause of morbidity and mortality in children. 1, 2 Various interventions have been attempted to reduce the risk of preterm birth in women at increased risk, including progesterone, cervical cerclage, and cervical pessary. Progesterone can be natural, administered vaginally [per vagina (PV)] or orally [per os (PO)], versus 17a-hydroxyprogesterone caproate (17-OHPC), administered intramuscularly (IM).
A previous network meta-analysis combining direct and indirect evidence for these interventions concluded that progesterone, particularly natural progesterone, was the best intervention for the primary prevention of preterm birth and neonatal death in women at risk overall and in women with a previous preterm birth. 3 However, since the last literature search, a number of studies have been published, including the PROGRESS Study, one of the biggest studies to date. 4 Therefore, our objectives were to provide an up-to-date network meta-analysis comparing the effectiveness of progesterone, cerclage, and pessary for preventing preterm birth in women at risk overall, and for women with a previous preterm birth and women with a short cervix, separating progesterone by route of administration.
We followed a similar protocol for this network metaanalysis as in our prior publication (CRD42015016166), 3 with the modifications specified below established before beginning. No patients were involved in the development of this study.
Information sources and search strategy
We searched Medline, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, and ISI Web of Science up to 1 January 2018 (Supporting Information Appendix S1) and screened the reference lists of systematic reviews and included studies.
Eligibility criteria
We included randomised controlled trials comparing progesterone, cerclage or pessary with a control group or another intervention for the prevention of preterm birth and/or associated adverse outcomes in at-risk singleton pregnancies. Women were considered at risk based on their history of preterm birth, cervical length or other factors defined by the authors. We included studies with any type of progesterone (natural or 17-OHPC) and route (PV, PO or IM), and any type of cerclage (McDonald or Shirodkar). The comparison group could have received placebo, bed rest, treatment as usual or a different type/route of the interventions listed above. We had no language exclusions.
We excluded studies in which a subgroup of women was already receiving an intervention before randomisation to our interventions of interest, unless this was based on objective risk factors (e.g. cervical length ≤20 mm) and unless results were reported separately for the groups of women with and without a pre-randomisation intervention. We included studies in which women received an additional intervention after randomisation, following the intentionto-treat principle, but excluded them in sensitivity analyses. We also excluded studies assessing interventions in the context of artificial reproductive therapy, assessing combinations of interventions or interventions for the secondary prevention of preterm birth (e.g. tocolytics in women with contractions), as well as non-peer-reviewed literature, studies published only as abstracts, and other study designs.
Given that the PROGRESS Study 4 included twin pregnancies (~2%, eight receiving progesterone and four receiving placebo) without stratifying results by twins, and as we did not receive a response from the authors to a request for singletons-only data, we subtracted, for the main analyses, the number of twin infants from the total sample size in each group, while maintaining the reported number of cases (as if none of the twins had the outcome). In sensitivity analyses, we considered the opposite scenario, subtracting the number of twin infants not only from the total sample size, but also from the number of cases (as if all twins had the outcome). Other studies included only singleton pregnancies, reported stratified data by pregnancy type, or the authors provided data.
Our primary outcomes were preterm birth <34 weeks (PTB <34 weeks) and <37 weeks (PTB <37 weeks), overall or specified as spontaneous. Our main infant secondary outcome was neonatal death (NND) and other outcomes included important infant and maternal adverse outcomes (see Supporting Information Tables S1 and S2 ). Although we had initially included medically indicated preterm birth in the protocol, after further consideration it was removed as it was not considered relevant here.
Data extraction and assessment of risk of bias
Two reviewers (AJ and OL) independently screened titles and abstracts, assessed the full text of potentially relevant papers and extracted the data from included studies using a piloted form. A third reviewer (SDM) resolved disagreements that could not be solved by discussion. We contacted authors of the original studies to confirm inclusion criteria if necessary.
We used the Cochrane Risk of Bias tool to assess each study's risk of bias, 5 considering studies to have a low risk of bias if none of the domains had a high risk and at least four domains (not counting 'Other') were low risk (with at least one being 'Random sequence generation' or 'Allocation concealment').
Data synthesis and statistical analyses
In the first set of analyses, we executed all the analyses and subgroup analyses from the previously published protocol, starting with overall network meta-analyses (any risk factor, any intervention type), and then focusing on women with a previous preterm birth and women with a cervical length ≤25 mm, and separating progesterone and cerclage by type, independent of the risk factors.
The second set of analyses focused on the comparison with the results of the PROGRESS Study, 4 in which vaginal progesterone was assessed in women with a previous preterm birth. Therefore, these additional, planned subgroup analyses involved splitting progesterone by route and separating studies by their participants' risk factors.
When there were at least 10 included studies for a given comparison, we performed Bayesian random-effects network meta-analyses. 6 We used the Markov chain Monte Carlo method, specifying vague prior distributions for intervention effects and assuming common heterogeneity parameters across each network to obtain pooled estimates. We used 100 000 iterations with a burn-in of 4000 iterations, using four chains and a thinning interval of 10. We assessed convergence using Gelman and Rubin's convergence diagnostic criteria. 7 When there were fewer than 10 included studies per comparison, we performed standard pairwise inverse variance random effects meta-analyses (DerSimonian and Laird). 8 We reported the posterior median odds ratios (OR) and median mean differences for binary and continuous outcomes, respectively. For each measure we reported its 95% credibility interval (CrI, in network meta-analyses) or confidence interval (CI, in pairwise meta-analyses), the number needed to treat (NNT, calculated in statistically significant results using the estimated effect size and the pooled prevalence in the control group), 5 and its quality rating [assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group approach]. 9 The CrI is the equivalent of the CI in the Bayesian framework, the NNT indicates how many additional women at risk would need to be treated to prevent one outcome, and the quality rating reflects the certainty that the results are close to the true effect.
Three basic assumptions underlie a network meta-analysis: first, that studies comparing interventions directly (direct estimates) are similar (absence of heterogeneity); second, that study characteristics and baseline characteristics are similar in the studies involved in the direct comparisons used to calculate indirect estimates (transitivity); and third, that the direct and indirect estimates of the same comparison are similar (coherence). If these assumptions are not met, the results of the network meta-analysis are challenged.
We used the I-squared statistic (I 2 ) to quantify the amount of heterogeneity in the direct comparisons. 10 To assess intransitivity in the indirect estimates we compared the inclusion criteria (risk factors) and baseline characteristics of the group of studies in each of the direct comparisons underlying the indirect comparison. We assessed incoherence between the direct and indirect effect estimates using the node-splitting method. 11 We then used the GRADE approach for network meta-analysis to rate the quality of the evidence, downgrading its rating if there was heterogeneity, intransitivity or incoherence, among other aspects such as high risk of bias in the included studies, small pooled sample size or publication bias in the direct comparisons, which we assessed using Duval and Tweedie's trim-and-fill method when there were at least 10 studies in a comparison. 9, 12, 13 Whenever we performed a network meta-analysis we ranked the interventions according to their Surface Under the Cumulative RAnking curve values (SUCRA).
14 An intervention consistently being among the most effective (in the multiple iterations of the Markov chain Monte Carlo) would have a higher SUCRA value.
We used R for all network meta-analyses (using the 'gemtc' package). 15 For all pairwise meta-analyses, we used REVIEW MANAGER (v.5.3).
Subgroup and sensitivity analyses
In addition to the subgroup analyses based on the participants' common risk factors (previous preterm birth or cervical length ≤25 mm) or intervention type (natural progesterone versus 17-OHPC, or McDonald versus Shirodkar cerclage), we separated progesterone by route (PO, PV, and IM), overall and in subgroups defined by the common risk factor of the participating women. We undertook these additional subgroup analyses for PTB <34 and PTB <37 weeks, and for NND, our key secondary outcome. To explore the possibility that the dose of PV progesterone (≤200 versus >200 mg/day) could explain the differences (heterogeneity) in PTB <37 weeks between studies in women with a previous preterm birth, we performed a post-hoc subgroup analysis.
We performed sensitivity analyses including only studies with low risk of bias and excluding studies with additional post-randomisation interventions. We repeated all the analyses and comparisons assuming that all the twins in the PROGRESS Study 4 had the outcome.
Results
Our search strategy identified 15 009 citations, of which 40 met our inclusion criteria, comprising 11 311 women (Figure 1) .
Study characteristics
Eighteen studies compared progesterone with a control group (ten studies used PV progesterone, including the PROGRESS Study, 4,16-24 six used IM 17-OHPC, [25] [26] [27] [28] [29] [30] and two used PO progesterone 31, 32 ), 11 studies compared cerclage with a control group (eight used McDonald cerclage, [33] [34] [35] [36] [37] [38] [39] [40] two used Shirodkar cerclage, 41, 42 and one used both 43 ) and four studies compared an inert pessary (Arabin) with a control group. [44] [45] [46] [47] One study compared cerclage (McDonald) with progesterone (IM 17-OHPC) 48 and six studies compared PV progesterone with IM 17-OHPC. [49] [50] [51] [52] [53] [54] Only four studies included women with a previous preterm birth excluding those with a short cervix (defined as <15, <20, <25, and <28 mm), and three studies included women with a short cervix excluding those with a history of preterm birth (including one study with women with a cervical length of <30 mm). Twelve studies included women with a previous preterm birth, regardless of cervical length, and ten studies included women with a short cervix (usually defined as ≤25 mm, although one study included women with a cervical length of <30 mm), regardless of their preterm birth history. The remaining 11 studies included women with a variety of risk factors (e.g. preterm birth in a sister 30 or using a scoring system of several risk factors, 38 Tables 1 and 2 ).
Overall analyses (women with any risk factor)
Progesterone (any of natural progesterone PO or PV or IM 17-OHPC) significantly reduced both PTB <34 (OR 0.45, 95% CrI 0.23-0.81; NNT 9; Moderate quality of evidence) and <37 weeks (OR 0.52, 95% CrI 0.36-0.73; NNT 8; Low quality of evidence), compared with control, ranking first and second, respectively, according to the SUCRA values. Pessary reduced PTB <37 weeks. Among studies labelling preterm birth specifically as 'spontaneous', pairwise metaanalyses resulted in progesterone significantly reducing PTB <34 weeks and pessary significantly reducing PTB <37 weeks, relative to control (Table S1 ). Among our secondary outcomes, progesterone (any type and route) significantly reduced the odds of NND compared with control, as well as showing significant benefits regarding admission to the neonatal intensive or special care unit, gestational age at birth and, in pairwise metaanalyses, PTB <33 and <35 weeks, birthweight <1500 g, respiratory distress syndrome, and early onset of sepsis. Cerclage significantly increased the gestational age at birth and, in pairwise meta-analyses, reduced PTB <33 weeks, while increasing the length of antepartum hospital stay. Full-text articles excluded (n = 338)
• Publication not full report (e.g. conference abstracts, editorials, etc.) (112) • Study design not randomized controlled trial (86) • Population not women at risk of preterm birth and eligible for primary prevention (44) • Twin population (27) • Intervention group not meeting inclusion criteria (11) • Comparison group not meeting inclusion criteria (10) • No relevant outcome data (9) • Overlap of samples (11) • Duplicate studies (21) • Ongoing trials (3)
• Not possible to locate (2) • Artificial reproduction therapy studies (2) Full-text screening: n = 378
Duplicate publications: n = 5101 Figure 1 . Flow diagram of the systematic review. Figure S1 and Table 3 ). See Supporting Information Figures S2-S4 for individual study data. Similar results by type of progesterone (natural progesterone PO or PV versus IM 17-OHPC) are presented in Table S3 . When separating cerclage into McDonald and Shirodkar cerclage, neither type had a significant effect on PTB <34 weeks, PTB <37 weeks or NND (Table S3) . We did detect significant incoherence in the comparison of McDonald versus Shirodkar for NND. However, no incoherence was found in any of the other network metaanalyses of this study, according to the node-splitting test.
Subgroup analyses by common risk factors
Women with a previous preterm birth In the subgroup of women with a 'previous preterm birth' (regardless of cervical length), progesterone (any type and route) significantly reduced the odds of PTB <34 weeks, PTB <37 weeks, and NND, compared with control. No study assessed pessary in this subpopulation and only two studies assessed cerclage, resulting in no significant benefit (Supporting Information Table S4 ).
When separating progesterone by its route (Table 3) , PV progesterone reduced PTB <34 (OR 0.29, 95% CI 0.12-0.68; NNT 8; Moderate quality of evidence) and <37 weeks (OR 0.43, 95% CrI 0.23-0.74; NNT 6; Moderate quality of evidence), but not NND. In addition, we found statistically significant differences in PTB <37 weeks between the studies using PV progesterone with a dose of ≤200 mg/day (OR 0.67, 95% CI 0.40-1.13) and those using a higher dose (OR 0.18, 95% CI 0.05-0.58). PO progesterone significantly reduced PTB <34 weeks (OR 0.42, 95% CI 0. 22 
Women with a short cervix (≤25 mm)
In the subgroup of studies with women with a cervical length ≤25 mm (regardless of history of preterm birth), the only statistically significant result was the reduction of PTB <34 weeks in women receiving progesterone (specifically PV progesterone) compared with control (Table 3, Supporting Information Table S5 ). See Supporting Information Figures S8-S10 for individual study data. ; only outcomes not reported in Rust 34 were used.
Sensitivity analyses
Of the 40 included studies, 28 were considered to have low risk of bias. The network including only low risk of bias studies found no significant effect of any of the interventions on reducing PTB <34 weeks. The results for PTB <37 weeks and NND remained similar to the original ones (Supporting Information Table S6 ). Given the lack of stratified data for singletons in the PROGRESS Study, we assumed none of the twins had the outcome and that, in sensitivity analysis, all had, and found Table 3 . Effectiveness of progesterone (PV, PO, IM 17-OHPC), cerclage, and pessary compared with control in women with a singleton pregnancy at overall risk of preterm birth and in subgroups defined by the common risk factor (previous preterm birth or cervical length ≤25 mm) Tables S7 and S8) . Six studies assessing progesterone reported the possibility or actual placement of a cerclage as an additional intervention. When reported, the proportion of women receiving such an additional intervention ranged from 2 to 17%, although it was similarly distributed between the groups. 18, 21, 28, 29, 32, 50 Removing these studies from the analyses did not change the conclusions for the effect of progesterone on PTB <34 or <37 weeks, but the odds of NND were no longer statistically significant.
As a minimum of ten studies is recommended to be able to assess the potential for publication bias 12 , the trim-andfill method was applied in only four comparisons. In three of these analyses the results changed from statistically significant to borderline significant after imputing additional studies, and the quality of evidence was lowered accordingly.
Discussion

Main findings
Our network meta-analysis of 40 trials on preterm birth prevention in singletons found that PV progesterone reduced PTB <34 weeks, PTB <37 weeks, and NND, making it the most consistently effective among the interventions studied in women at overall risk of preterm birth. In women with a short cervix (≤25 mm), PV progesterone reduced PTB <34 weeks, but data were sparse. In women with a previous preterm birth, PV progesterone significantly reduced PTB <34 and <37 weeks, although not NND. IM 17-OHPC significantly reduced PTB <37 weeks and NND; PTB <34 weeks could not be assessed due to lack of data. Pessary and PO progesterone showed significant results in only one comparison each.
Strengths and limitations
The main strength of this study is its design with both an overarching synthesis of the published trials on interventions to prevent preterm birth (progesterone, cerclage, and pessary), and a detailed analysis by types and routes of administration, and by subgroups based on risk factors (i.e. previous preterm birth or short cervix). Another strength of our study was the combination of direct and indirect estimates using network meta-analyses, and assessing the underlying assumptions and the quality of evidence using the GRADE approach.
Our study has several limitations, as we were limited by the data and subgroups reported in the included studies, yielding sparse data for some subgroups, such as in women with a short cervix, and consequently wider CrI/CI and uncertainty in the results. Similarly, there is a disparity in the outcomes reported in studies using different interventions. For instance, whereas half of the studies assessing the effect of PV progesterone on PTB <34 and/or <37 weeks reported results for both outcomes, only one study assessing the effects of 17-OHPC did so. This disparity in the amount of data for each intervention and outcome puts some restraints on our results. Finally, in some cases the assumptions underlying a number of network meta-analyses were challenged, and the quality of evidence was 'low' or 'very low'. However, in life-threatening situations and no evidence of harm it is justified to make strong recommendations in favour of an intervention even when there is 'low' or 'very low' quality of evidence. 
Interpretation in light of other evidence
We identified PV progesterone as an effective intervention to prevent preterm birth. Including the PROGRESS Study, 4 five studies assessed PV progesterone in women with previous preterm birth and reported PTB <37 weeks (the PRO-GRESS Study did not report PTB <34 weeks), with a pooled effect size of 0.43 (95% CrI 0.23-0.74, Moderate quality of evidence), although with substantial heterogeneity. Three studies had positive, statistically significant effects with progesterone, 19, 23, 24 while the remaining two, which account for 86% of the sample, centred on the null effect. 4, 17 One possible explanation is publication bias. Alternatively, when comparing the characteristics of the two groups of studies we found that studies including women with previous preterm births and using vaginal suppositories reported significant, positive results, whereas those using vaginal gel or pessary did not.
A subgroup analysis by dose of progesterone (≤200 versus >200 mg/day) found statistically significant differences between the groups in favour of higher doses, although as all but one of the studies (Azargoon 19 used 400 mg/day) used very similar low doses (90 or 100 mg/day), this does not explain the differences between the large non-significant studies and the smaller significant ones.
Recently Romero et al. 56 pooled individual participant data from five studies (all of which were included in our overall analyses, although stratified data for women with a short cervix were available for only two of them), 18, 20 and found similarly significant results for PTB <34 weeks, and non-significant ones for PTB <37 weeks and NND. Besides these outcomes, however, they found a benefit with vaginal progesterone on many outcomes. 56 
Areas for future research
Further research is required to explore PV progesterone's heterogeneity, examine interventions for short cervices, confirm the reduction in neonatal death with 17-OHPC, and randomly investigate combinations of therapies.
Conclusions
Overall, we found that progesterone, particularly PV progesterone, was a consistently effective intervention to prevent preterm birth as well as neonatal death, in women with a singleton pregnancy at risk overall and in women at risk due to a previous preterm birth. In the subpopulation of women with a short cervix there was no clear evidence of benefit. The quality of evidence varied between low and high.
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No ethical approval was required for this study. Award #950-229920. None of the agencies had any influence on the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Figure S1 . Network graphs for preterm birth <34 weeks, preterm birth <37 weeks, and neonatal death (separating progesterone by route of administration: per vagina (PV), per os (PO), and intramuscular 17-OHPC). Figure S2 . Forest plot of each comparison (separating progesterone by route of administration) on preterm birth <34 weeks in women overall at risk (reported network estimates differ from these results due to the influence of indirect estimates). Figure S3 . Forest plot of each comparison (separating progesterone by route of administration) on preterm birth <37 weeks in women overall at risk (reported network estimates differ from these results due to the influence of indirect estimates). Figure S4 . Forest plot of each comparison (separating progesterone by route of administration) on neonatal death in women overall at risk (reported network estimates differ from these results due to the influence of indirect estimates). Figure S5 . Forest plot of each comparison (separating progesterone by route of administration) on preterm birth <34 weeks in women with a previous preterm birth. Figure S6 . Forest plot of each comparison (separating progesterone by route of administration) on preterm birth <37 weeks in women with a previous preterm birth (reported network estimates differ from these results due to the influence of indirect estimates). One of the studies (Shahgheibi et al. 30 ) did not specify the number of cases in each group for this subgroup, but reported instead only OR (95% CI). Figure S7 . Forest plot of each comparison (separating progesterone by route of administration) on neonatal death in women with a previous preterm birth. Figure S8 . Forest plot of each comparison (separating progesterone by route of administration) on preterm birth <34 weeks in women with a cervical length ≤25 mm. Figure S9 . Forest plot of each comparison (separating progesterone by route of administration) on preterm birth <37 weeks in women with a cervical length ≤25 mm. Figure S10 . Forest plot of each comparison (separating progesterone by route of administration) on neonatal death in women with a cervical length ≤25 mm. Table S1 . Effectiveness of progesterone, cerclage, and pessary compared with control for primary outcomes and secondary outcomes for which network meta-analysis was performed. Table S2 . Effectiveness of progesterone, cerclage, and pessary compared to control for secondary outcomes for which meta-analysis was performed. Table S3 . Effectiveness of progesterone, cerclage, and pessary compared to control after separating the interventions by type. Table S4 . Effectiveness of progesterone, cerclage, and pessary compared with control in women with a previous preterm birth. Table S5 . Effectiveness of progesterone, cerclage, and pessary compared to control in women with a cervical length ≤25 mm. Table S6 . Effectiveness of progesterone, cerclage, and pessary compared with control in studies with a low risk of bias. Table S7 . Comparison of the results assuming that none of the twins or all of the twins included in Crowther et al. 4 had the given outcome: Network meta-analyses. Table S8 . Comparison of the results assuming that none of the twins or all twins included in Crowther et al. 4 had the given outcome: pairwise meta-analysis.
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